The Centers for Medicare & Medicaid Services (CMS) has created codes for administering bebtelovimab, a monoclonal antibody injection recently authorized for treating mild-to-moderate COVID-19 in some patients. The codes, effective Feb. 11, are:
For more information, visit the CMS COVID-19 Monoclonal Antibodies webpage.
The Food and Drug Administration (FDA) authorized the emergency use of bebtelovimab for patients 12 and over. The treatment is authorized when all of these conditions apply:
Bebtelovimab was observed to be effective against both the omicron variant and the BA.2 omicron subvariant.
— Kent Moore, senior strategist for physician payment, American Academy of Family Physicians
Posted on Feb. 21, 2022, by Kent Moore
Sign up to receive FPM's free, weekly e-newsletter, "Quick Tips & Insights," featuring practical, peer-reviewed advice for improving practice, enhancing the patient experience, and developing a rewarding career.